Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

21 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Patients With High Cardiovascular Risk as Candidates to Bempedoic Acid, After Treatment With Statins, Ezetimibe and PCSK9 Inhibitors: An Estimation and Cost-Effectiveness Analysis.
Seijas-Amigo J, Cordero A, Olmo RF, Cortez Quiroga GA, Fácila L, Salgado-Barreira Á, Reyes-Santías F, Romero-Menor C, Murillo JR, Rodríguez-Mañero M, Bello Mora MC, Valle A, Sandin M, Pamias RF, Bañeras J, García PB, Lorenzo MC, Sánchez-Alvarez S, López-Rodríguez L, González-Juanatey JR. Seijas-Amigo J, et al. J Cardiovasc Pharmacol. 2023 Jan 1;81(1):70-75. doi: 10.1097/FJC.0000000000001365. J Cardiovasc Pharmacol. 2023. PMID: 36219195
Estimation of the major cardiovascular events prevention with Inclisiran.
Cordero A, Santos-Gallego CG, Fácila L, Rodríguez-Mañero M, Bertomeu-González V, Castellano JM, Seijas-Amigo J, Núñez J, Zuazola P, González-Juanatey JR, Badimon JJ. Cordero A, et al. Atherosclerosis. 2020 Nov;313:76-80. doi: 10.1016/j.atherosclerosis.2020.09.021. Epub 2020 Sep 25. Atherosclerosis. 2020. PMID: 33032236
Prevention of myocardial infarction and stroke with PCSK9 inhibitors treatment: a metanalysis of recent randomized clinical trials.
Cordero A, Rodríguez-Mañero M, Fácila L, Fernández-Olmo MR, Gómez-Martínez MJ, Valle A, Castellano JM, Toro MM, Seijas-Amigo J, Vicedo A, González-Juanatey JR. Cordero A, et al. J Diabetes Metab Disord. 2020 Jun 1;19(2):759-765. doi: 10.1007/s40200-020-00557-6. eCollection 2020 Dec. J Diabetes Metab Disord. 2020. PMID: 33520801 Free PMC article.
Sex Differences in Low-Density Lipoprotein Cholesterol Reduction With PCSK9 Inhibitors in Real-world Patients: The LIPID-REAL Registry.
Cordero A, Fernández Del Olmo MR, Cortez Quiroga GA, Romero-Menor C, Fácila L, Seijas-Amigo J, Fornovi A, Murillo JR, Rodríguez-Mañero M, Bello Mora MC, Valle A, Miriam S, Pamias RF, Bañeras J, García PB, Clemente Lorenzo MM, Sánchez-Alvarez S, López-Rodríguez L, González-Juanatey JR. Cordero A, et al. J Cardiovasc Pharmacol. 2022 Apr 1;79(4):523-529. doi: 10.1097/FJC.0000000000001205. J Cardiovasc Pharmacol. 2022. PMID: 34983910
Impact of the COVID-19 pandemic in the lipid control of the patients that start PCSK9 inhibitors.
Seijas-Amigo J, Gayoso-Rey M, Mauriz-Montero MJ, Suarez-Artime P, Casas-Martinez A, Dominguez-Guerra M, Gonzalez-Freire L, Estany-Gestal A, Codero-Fort A, Rodriguez-Mañero M, Gonzalez-Juanatey JR; e investigadores MEMOGAL. Seijas-Amigo J, et al. Clin Investig Arterioscler. 2022 Sep-Oct;34(5):245-252. doi: 10.1016/j.arteri.2022.01.003. Epub 2022 Feb 3. Clin Investig Arterioscler. 2022. PMID: 35287972 Free PMC article. English, Spanish.
Polypill Strategy in Secondary Cardiovascular Prevention.
Castellano JM, Pocock SJ, Bhatt DL, Quesada AJ, Owen R, Fernandez-Ortiz A, Sanchez PL, Marin Ortuño F, Vazquez Rodriguez JM, Domingo-Fernández A, Lozano I, Roncaglioni MC, Baviera M, Foresta A, Ojeda-Fernandez L, Colivicchi F, Di Fusco SA, Doehner W, Meyer A, Schiele F, Ecarnot F, Linhart A, Lubanda JC, Barczi G, Merkely B, Ponikowski P, Kasprzak M, Fernandez Alvira JM, Andres V, Bueno H, Collier T, Van de Werf F, Perel P, Rodriguez-Manero M, Alonso Garcia A, Proietti M, Schoos MM, Simon T, Fernandez Ferro J, Lopez N, Beghi E, Bejot Y, Vivas D, Cordero A, Ibañez B, Fuster V; SECURE Investigators. Castellano JM, et al. N Engl J Med. 2022 Sep 15;387(11):967-977. doi: 10.1056/NEJMoa2208275. Epub 2022 Aug 26. N Engl J Med. 2022. PMID: 36018037 Clinical Trial.
Effect of PCSK9 inhibitors on remnant cholesterol and lipid residual risk: The LIPID-REAL registry.
Cordero A, Fernández Olmo MR, Cortez Quiroga GA, Romero-Menor C, Fácila L, Seijas-Amigo J, Rondán Murillo J, Sandin M, Rodríguez-Mañero M, Bello Mora MC, Valle A, Fornovi A, Freixa Pamias R, Bañeras J, Blanch García P, Clemente Lorenzo MM, Sánchez-Álvarez S, López-Rodríguez L, González-Juanatey JR. Cordero A, et al. Among authors: seijas amigo j. Eur J Clin Invest. 2022 Dec;52(12):e13863. doi: 10.1111/eci.13863. Epub 2022 Sep 5. Eur J Clin Invest. 2022. PMID: 36039486
Differences in weight loss and safety between the glucagon-like peptide-1 receptor agonists: A non-randomized multicenter study from the titration phase.
Seijas-Amigo J, Salgado-Barreira Á, Castelo-Dominguez R, Pérez-Álvarez MT, Ponce-Piñón B, Fernández-Silva M, Rodríguez-Barreiro M, Pereira-Pía M, Iglesias-Moreno JM, Gago-García M, Montáns-García R, Fernandez-Perez A, FragaGayoso D, Fernandez-Montenegro M, Riveiro-Barciela B, Rilla-Villar N, Cordero A, RodríguezMañero M, González-Juanatey JR. Seijas-Amigo J, et al. Prim Care Diabetes. 2023 Aug;17(4):366-372. doi: 10.1016/j.pcd.2023.05.004. Epub 2023 May 23. Prim Care Diabetes. 2023. PMID: 37230813 Free article.
21 results